OCUL: FDA-aligned NDA for AXPAXLI targets Q4, backed by strong data and broad launch readiness
Alignment with the FDA enables a Q4 NDA submission for AXPAXLI in wet AMD, leveraging strong single-trial data and the 505(b)(2) pathway. The product shows superior durability, robust safety, and is expected to see broad adoption, with commercial and financial readiness in place.Based on Ocular The…